




ERS Research Seminar

***New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine***

09 – 10 May 2019; Paris, France

**Day 1 – Thursday, 09 May 2018**

08:30-08:45:	Registration
08:45-09:00:	Introduction (Jacques Cadranel and Thierry Berghmans)
	<b>Session 1: From molecular alterations to cancer immunity in NSCLC</b> <b>Chairs:</b> P. Pauwels and T. Berghmans
09:00-09:25:	What are the main mechanisms of oncogenic addiction? (Joanna Chorostowska, PL)
09:25-09:50:	Are KRAS mutations druggable? (Marina Garassino, IT)
09:50-10:15:	How does the cancer immunity circle operate (or dysoperate)? (Joachim Aerts, NL)
10:15-10:40:	<i>Panel discussion</i>
10:40-11:00:	<i>Coffee break</i>
	<b>Session 2: From molecular target to molecular resistance in NSCLC</b> <b>Chairs:</b> J. Aerts and D. Planchard
11:00-11:25:	Molecular diagnosis for oncogenic addictions (Patrick Pauwels, BL)
11:25-11:50:	When and how to identify resistance mechanisms to targeted therapies (Nicolas Girard, FR)
11:50-12:15:	Predictive biomarker of immune checkpoint inhibitors efficacy (Luis Paz-Ares, SP)
12:15-12:40:	<i>Panel discussion</i>
12:40-14h00:	<i>Lunch</i>
	<b>Session 3: From molecular addiction to therapeutic strategy in NSCLC</b> <b>Chairs:</b> M. Garassino, J. Chorostowska
14:00-14:25:	Therapeutic strategy for EGFR driven NSCLC (Jacques Cadranel, FR)
14:25-14:50:	Therapeutic strategy for ALK/ROS driven NSCLC (Jan Van Meerbeeck, BL)
14:50-15:15:	Therapeutic strategy for other oncogenic drivers (David Planchard, FR)
15:15-15:40:	<i>Panel discussion</i>
15:40-16:00:	<i>Coffee break</i>
16:00-17:45:	<b>Session 4 – Breakout – Difficult situations in the era of targeted therapies</b> Group 1. How to manage brain metastasis – <i>L. Hendriks and T. Berghmans</i> Group 2. How to manage diagnostic resistance – <i>J. Chorostowska and N. Girard</i> Group 3. How to manage specific toxicities of targeted therapies – <i>A.M. Dingemans and D. Planchard</i> Group 4. Which sequence for TKI, ICI and conventional chemotherapy – <i>L. Paz Ares and J. Cadranel</i>
17:45-18:00:	Urgent questions
From 19h00:	<i>Dinner</i>

## Day 2 – Friday, 10 May 2018



### **Session 5: From PD1/PD-L1 monotherapy in selected patients to PD1/PD-L1 combo for all NSCLC**

**Chairs:** J. Van Meerbeeck and J. Cadranel

- 09:00-09:25: From anti-PD1/L1 inhibitors to new immunotherapies  
(Thierry Berghmans, BL)
- 09:25-09:50: Which immunotherapy for which patients? (Lizza Hendriks, NL)
- 09:50-10:15: Combination therapy in the era of immunotherapy  
(Anne-Marie Dingemans, NL)

10:15-10:30: *Panel discussion*

10:30-10:50: *Coffee break*



### **Session 6: General podium discussion on research priorities**

**Chairs:** J. Cadranel and T. Berghmans

- 10:50-11:50: Summary of working groups: 15' per group
- 11:50-12:35: Whole faculty and all participants

12:35-14:00: *Lunch and departure*